Elsevier

The Lancet

Volume 365, Issue 9453, 1 January 2005, Pages 60-62
The Lancet

Fast track — Research Letters
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

https://doi.org/10.1016/S0140-6736(04)17666-6Get rights and content

Summary

The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0·87, 95% CI 0·78–0·97, p=0·01) and time-to-recurrence (402 vs 498, 0·79, 0·70–0·90, p=0·0005), and significantly reduced distant metastases (324 vs 375, 0·86, 0·74–0·99, p=0·04) and contralateral breast cancers (35 vs 59, 42% reduction, 12–62, p=0·01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.

Published online December 8, 2004 http://image.thelancet.com/extras/04let11120web.pdf

References (5)

  • EP Winer et al.

    American Society of Clinical Oncology Technology on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor-positive breast cancer: status report 2004

    J Clin Oncol

    (2004)
  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

    Lancet

    (2002)
There are more references available in the full text version of this article.

Cited by (0)

View full text